High prevalence of left ventricular hypertrophy in patients with hypertension of long evolution;Elevada prevalencia de hipertrofia ventricular izquierda en pacientes con hipertensión arterial de larga evolución

Medicina Clinica

Volumn 129, Issue 2, 2007, Pages 46-50

  Fernández Villaverde, José María ^a   Maestro Saavedra, Francisco Javier ^a   Vidal, Germán Allut ^a   Shamagian, Lilian Grigorian ^b   Otero Raviña, Fernando ^c   González Juanatey, José Ramón ^b  

^a Centro de Salud   (Spain)

^b University Hospital of Santiago de Compostela   (Spain)

^c Servicio Gallego de Salud   (Spain)

Author keywords

Cardiovascular risk; Hypertension; Left ventricular hypertrophy

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR RISK; CLINICAL EVALUATION; CONSERVATIVE TREATMENT; CONTROLLED STUDY; DEMOGRAPHY; DISEASE COURSE; DISEASE SURVEILLANCE; ELECTROCARDIOGRAM; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; OBESITY; PREVALENCE; RISK ASSESSMENT; SEX DIFFERENCE;

EID: 34548566157     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1157/13106936     Document Type: Article

References (33)

1. Swynghedauw B. Molecular mechanism of myocardial remodeling. Physiol Rev. 1999;79:215-62.
2. Dalfó A, Bayó J, Gil M, Campillo M, Botey A, Vila MA, et al. Hipertrofia ventricular izquierda en una población hipertensa general de Barcelona. Med Clin (Barc). 1995;105:361-6.
3. Aronow WS, Epstein S, Koenigsberg M, Schwartz KS. Usefulness of echocardiographic left ventricular hypertrophy, ventricular tachycardia and complex ventricular arrhytmias in predicting ventricular fibrillation or sudden cardiac death in elderly patients. Am J Cardiol. 1988;62:1124-5.
4. Kannel WB. Prevalence and natural history of electrocardiographic left ventricular hypertrophy. Am J Med. 1983;75 Suppl 3A:4-11.
5. Gardin JM, Lauer MS. Left ventricular hypertrophy: the next treatable, silent killer? JAMA. 2004;292:2396-8.
6. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA. 2004;292:2343-9.
7. Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papademetriou V, et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA. 2004;292:2350-6.
8. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560-72.
9. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21:1011-53.
10. González-Juanatey JR, Mazón Ramos P, Soria Arcos F, Barrios Alonso V, Rodríguez Padial L, Bertomeu Martínez V. Actualización (2003) de las Guías de Práctica Clínica de la Sociedad Española de Cardiología en hipertensión arterial. Rev Esp Cardiol. 2003;56:487-97.
11. Levy D, Labib SB, Andersen KM, Christiansen JC, Kannel WB, Castelli WP. Determinants of sensitivity and specificity of electrocardiographic criteria for left ventricular hypertrophy. Circulation. 1990;81:815-20.
12. Schillaci G, Verdecchia P, Borgioni C, Ciucci A, Guerrieri M, Zampi I, et al. Improved electrocardiographic diagnosis of left ventricular hypertrophy. Am J Cardiol. 1994;74:714-9.
13. Shan DJ, De Maria A, Kisslo J, Weyman A. Recommendations regarding quantitation in Mmode echocardiography: results of a survey of echocardiographic measurements. Circulation. 1978;58:1072-83.
14. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, et al. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms: recommendations for quantitation of the left ventricle by two-dimensional echocardiography. J Am Soc Echocardiogr. 1989;2:358-67.
15. Verdecchia P, Angeli F, Reboldi G, Carluccio E, Benemio G, Gattobigio R, et al. Improved cardiovascular risk stratification by a simple ECG index in hypertension. Am J Hypertens. 2003;16:646-52.
16. Mazón Ramos P, Bertomeu Martínez V, González- Juanatey JR, Aznar Costa J, Cea Calvo L. Estudio de prevalencia y características del paciente con hipertensión e hipertrofia ventricular izquierda. Análisis del manejo clínico de estos pacientes. Rev Esp Cardiol. 2005;58 Supl 1:178.
17. Lozano JV, Redón J, Cea-Calvo L, Fernández-Pérez C, Navarro J, Bonet A, et al. Hipertrofia ventricular izquierda en la población hipertensa española. Estudio ERIC-HTA. Rev Esp Cardiol. 2006;59:136-42.
18. Levy D, Salomón M, D'Agostino RB, Belanger AJ, Kannel WB. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation. 1994;90:1786-93.
19. Mathew J, Sleight P, Lonn E, Johnstone D, Pogue J, Bosch J, et al. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation. 2001;104:1615-21.
20. Tovillas FJ, Dalfó A, Romea S, Siso A, Senar E, Miracle M. Morbilidad cardiovascular y su relación con la hipertrofia ventricular izquierda de una cohorte de pacientes hipertensos: estudio Gòtic. Aten Primaria. 2001;28:315-9.
21. De Simone G, Verdecchia P, Pede S, Gorini M, Maggioni AP. Prognosis of inappropriate left ventricular mass in hypertension. The MAVI study. Hypertension. 2002;40:470-6.
22. Schillaci G, De Simone G, Reboldi G, Porcellati C, Devereux RB, Verdecchia P. Change in cardiovascular risk profile by echocardiography in low- or medium-risk hypertension. J Hypertens. 2002;20:1519-25.
23. Verdecchia P, Carini G, Circo A, Dovellini E, Giovannini E, Lombardo M, et al. Left ventricular mass and cardiovascular morbidity in essential hypertension. J Am Coll Cardiol. 2001;38:1829-35.
24. Klingbeil AU, Schneider M, Martus P, Schmieder RE. A meta-analysis of the effects of treatment of left ventricular mass in essential hypertension. Am J Med. 2003;115:41-6.
25. González-Juanatey JR, Pose A, García JM, González-Juanatey C, Valdés L, Cabezas J. Step-down enalapril treatment for arterial hypertension. Hypertension. 1999;34:1287-92.
26. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al, for the LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
27. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, De Faire U, et al, for the LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:1004-10.
28. Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlof B, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol. The Losartan Intervention for End Point Reduction in Hypertension (LIFE) Study. J Am Coll Cardiol. 2005;45:712-9.
29. Wachtell K, Hornestam B, Lehto M, Slotwiner DJ, Gerdts E, Olsen MH, et al. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation. The Losartan Intervention for End Point Reduction in Hypertension (LIFE) Study. J Am Coll Cardiol. 2005;45:705-11.
30. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366:895-906.
31. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113:1213-25.
32. Roman MJ, Kizer JR, Ali T, Lee ET, Galoway JM, Rabsitz RR, et al. Central blood pressure better predicts cardiovascular events than does peripheral blood pressure: the Strong Heart Study [resumen]. Circulation. 2005;112 Suppl II:778.
33. Danchin N, Benetos A, López-Sublet M, Demicheli T, Safar M, Mourad JJ. Aortic pulse pressure is related to the presence and extent of coronary artery disease in men undergoing diagnostic coronary angiography: a multicenter study. Am J Hypertens. 2004;17:129-33.